✦ LIBER ✦

Renal function after release of chronic unilateral hydronephrosis in man

✍ Scribed by Gillenwater, Jay Y; Westervelt, Frederic B; Vaughan, E Darracott; Howards, Stuart S

Book ID: 109876953
Publisher: Nature Publishing Group
Year: 1975
Tongue: English
Weight: 630 KB
Volume: 7
Category: Article
ISSN: 0085-2538
DOI: 10.1038/ki.1975.26

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Delayed decrease in differential renal f

Delayed decrease in differential renal function after successful pyeloplasty in children with unilateral antenatally detected hydronephrosis

✍ Fumi Matsumoto; Kenji Shimada; Mari Kawagoe; Futoshi Matsui; Akira Nagahara 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

Adaptation of renal function after unila

Adaptation of renal function after unilateral nephrectomy in children with renal tumors

✍ Raymond M. Donckerwolcke; Max J. Coppes 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 54 KB

The influnce of volume expanison on rena

The influnce of volume expanison on renal function after relief of chronic unilateral ureteral obstruction

✍ Wilson, Douglas R 📂 Article 📅 1974 🏛 Nature Publishing Group 🌐 English ⚖ 675 KB

Renal function in chronic hydronephrosis

Renal function in chronic hydronephrosis with and without infection and the role of the lymphatics. An experimental study in dogs

✍ Naber, K.G. ;Madsen, P.O. 📂 Article 📅 1974 🏛 Springer 🌐 English ⚖ 645 KB

Improvement of renal function after the

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro